96 related articles for article (PubMed ID: 11910332)
1. Ovarian cancer as a chronic disease: a new treatment paradigm. Highlights of a roundtable discussion.
Spriggs DR
Cancer Control; 2001; 8(6 Suppl 1):5-7; discussion 8-18. PubMed ID: 11910332
[No Abstract] [Full Text] [Related]
2. Nursing perspectives on patient management during chronic therapy for relapsed ovarian cancer.
Frazier SR
Cancer Control; 2001; 8(6 Suppl 1):19-21. PubMed ID: 11910333
[No Abstract] [Full Text] [Related]
3. Recurrent ovarian cancer.
Tummala MK; McGuire WP
Clin Adv Hematol Oncol; 2005 Sep; 3(9):723-36. PubMed ID: 16224447
[TBL] [Abstract][Full Text] [Related]
4. [A recurrent ovarian cancer patient who achieved a complete response following irinotecan plus CDDP therapy].
Kawashima T; Murakami H; Kanamori T; Nakamura Y
Gan To Kagaku Ryoho; 2007 Mar; 34(3):461-3. PubMed ID: 17353644
[TBL] [Abstract][Full Text] [Related]
5. Usefulness of third-line chemotherapy for women with recurrent ovarian, fallopian tube, and primary peritoneal cancer who receive platinum/taxane regimens as first-line therapy.
Nishio S; Katsumata N; Matsumoto K; Tanabe H; Yonemori K; Kouno T; Shimizu C; Ando M; Kamura T; Kasamatsu T; Fujiwara Y
J Cancer Res Clin Oncol; 2009 Apr; 135(4):551-7. PubMed ID: 18830625
[TBL] [Abstract][Full Text] [Related]
6. The timing of normalization of CA-125 levels during primary chemotherapy is predictive of survival in patients with epithelial ovarian cancer.
Rocconi RP; Matthews KS; Kemper MK; Hoskins KE; Huh WK; Straughn JM
Gynecol Oncol; 2009 Aug; 114(2):242-5. PubMed ID: 19447480
[TBL] [Abstract][Full Text] [Related]
7. Sequential topotecan and oral etoposide in recurrent ovarian carcinoma pretreated with platinum-taxane. Results from a multicenter phase I/II study.
Gronlund B; Engelholm SA; Horvath G; Mäenpää J; Ridderheim M
Cancer; 2005 Apr; 103(7):1388-96. PubMed ID: 15719439
[TBL] [Abstract][Full Text] [Related]
8. Low drug resistance to both platinum and taxane chemotherapy on an in vitro drug resistance assay predicts improved survival in patients with advanced epithelial ovarian, fallopian and peritoneal cancer.
Matsuo K; Bond VK; Eno ML; Im DD; Rosenshein NB
Int J Cancer; 2009 Dec; 125(11):2721-7. PubMed ID: 19530239
[TBL] [Abstract][Full Text] [Related]
9. Ovarian-cancer results cause a stir at cancer conference.
McNamee D
Lancet; 2000 May; 355(9218):1890. PubMed ID: 10866453
[No Abstract] [Full Text] [Related]
10. Lights and shadows of the tumoral marker CA-125 in ovarian cancer.
Sánchez Muñoz A; González Martín A; Mendiola Fernández C
Clin Transl Oncol; 2008 Aug; 10(8):449-52. PubMed ID: 18667373
[No Abstract] [Full Text] [Related]
11. CA 125 and the detection of recurrent ovarian cancer: a reasonably accurate biomarker for a difficult disease.
Bast RC
Cancer; 2010 Jun; 116(12):2850-3. PubMed ID: 20564390
[No Abstract] [Full Text] [Related]
12. [Usefulness of CA-125 antigen for monitoring neoplastic processes in patients with ovarian tumors].
Kwaśniewska-Rokicińska C; Bartnikowa W; Koterbicka A; Deja R
Ginekol Pol; 1994 Mar; 65(3):136-41. PubMed ID: 8001848
[No Abstract] [Full Text] [Related]
13. No evidence for taxane/platinum pharmacogenetic markers: just lack of power?
Vach W; Bergmann TK; Brøsen K
J Clin Oncol; 2008 Apr; 26(11):1903-4; author reply 1904-5. PubMed ID: 18398158
[No Abstract] [Full Text] [Related]
14. Randomized phase III trial of tamoxifen versus thalidomide in women with biochemical-recurrent-only epithelial ovarian, fallopian tube or primary peritoneal carcinoma after a complete response to first-line platinum/taxane chemotherapy with an evaluation of serum vascular endothelial growth factor (VEGF): A Gynecologic Oncology Group Study.
Hurteau JA; Brady MF; Darcy KM; McGuire WP; Edmonds P; Pearl ML; Ivanov I; Tewari KS; Mannel RS; Zanotti K; Benbrook DM
Gynecol Oncol; 2010 Dec; 119(3):444-50. PubMed ID: 20846715
[TBL] [Abstract][Full Text] [Related]
15. Recent advances in the management of women with ovarian cancer.
Eltabbakh GH
Minerva Ginecol; 2004 Feb; 56(1):81-9. PubMed ID: 14973412
[TBL] [Abstract][Full Text] [Related]
16. Carboplatin reinduction after taxane in patients with platinum-refractory epithelial ovarian cancer.
Kavanagh J; Tresukosol D; Edwards C; Freedman R; Gonzalez de Leon C; Fishman A; Mante R; Hord M; Kudelka A
J Clin Oncol; 1995 Jul; 13(7):1584-8. PubMed ID: 7602347
[TBL] [Abstract][Full Text] [Related]
17. [The value of serum tissue polypeptide specific antigen TPS concentration in therapeutic monitoring of patients with epithelial malignant ovarian neoplasms].
Zakrzewska I; Borawska R
Ginekol Pol; 2000 Dec; 71(12):1523-31. PubMed ID: 11216170
[TBL] [Abstract][Full Text] [Related]
18. Predictive value of microtubule-associated protein Tau in patients with recurrent and metastatic breast cancer treated with taxane-containing palliative chemotherapy.
Zhou J; Qian S; Li H; He W; Tan X; Zhang Q; Han G; Chen G; Luo R
Tumour Biol; 2015 May; 36(5):3941-7. PubMed ID: 25773385
[TBL] [Abstract][Full Text] [Related]
19. Options for primary chemotherapy of epithelial ovarian cancer: taxanes.
Trimble EL; Arbuck SG; McGuire WP
Gynecol Oncol; 1994 Dec; 55(3 Pt 2):S114-21. PubMed ID: 7835794
[TBL] [Abstract][Full Text] [Related]
20. The effect of hospital operative volume, residual tumor and first-line chemotherapy on survival of ovarian cancer - a prospective nation-wide study in Finland.
Kumpulainen S; Sankila R; Leminen A; Kuoppala T; Komulainen M; Puistola U; Hurme S; Hiekkanen H; Mäkinen J; Grénman S
Gynecol Oncol; 2009 Nov; 115(2):199-203. PubMed ID: 19695688
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
